CRISPR/Cas9 technology has shown clear potential for creating AD mouse models that can highly mimic human AD pathology, and has been used to precisely control pathological processes such as Aβ formation and tau protein phosphorylation, shedding light on potential therapeutic approaches. This evidence concerns the gene MAPT and Alzheimer disease.